Agarwal Arjun 4
4 · Oruka Therapeutics, Inc. · Filed Jun 15, 2026
Research Summary
AI-generated summary of this filing
Oruka (ORKA) SVP Finance Arjun Agarwal Exercises Options, Sells Shares
What Happened
Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics (ORKA), exercised options on June 12, 2026 to acquire 9,459 shares (8,000 shares at $12.50 for $100,000; 1,459 shares at $34.39 for $50,175; total paid $150,175). Between June 12 and June 15 he sold a total of 9,854 shares in open-market transactions for aggregate proceeds of roughly $687,036 (sales reported at weighted-average prices of $68.34, $69.85, $70.34 and $69.69 across different tranches). The filing also shows corresponding derivative conversion/disposition entries at $0.00 that reflect the option exercises/conversions.
Key Details
- Transaction dates: primarily June 12, 2026 (exercises and multiple sales) and one sale on June 15, 2026. Filing date: June 15, 2026 (timely).
- Option exercises (acquisitions): 8,000 @ $12.50 ($100,000) and 1,459 @ $34.39 ($50,175).
- Open-market sales (dispositions):
- 1,859 shares at weighted avg $68.34 (proceeds ~$127,048) — prices ranged $67.87–$68.71 (F3)
- 4,340 shares at weighted avg $69.85 (proceeds ~$303,154) — prices ranged $69.07–$70.06 (F4)
- 3,260 shares at weighted avg $70.34 (proceeds ~$229,306) — prices ranged $70.07–$70.86 (F5)
- 395 shares at $69.69 (proceeds ~$27,528)
- Net effect: Acquired 9,459 shares and sold 9,854 shares — a net disposition of 395 shares. The filing does not state total shares owned after these transactions.
- Notable footnotes: some sales were executed under a Rule 10b5‑1 trading plan dated Feb 11, 2026 (F2); certain reported sales were automatic sell‑to‑cover transactions to satisfy tax withholding from RSU vesting (F6); 888 shares reported include purchases under the company's employee stock purchase plan on June 8, 2026 (F1). Option vesting schedules referenced (F7, F8).
- Timeliness: Filed June 15 for transactions dated June 12 — within the Form 4 filing window (timely).
Context
- This sequence is a common "exercise-and-sell" pattern (options exercised and many of the resulting shares sold). The $0.00 derivative disposal lines reflect conversion/exercise mechanics rather than a cash sale price. Some sales were pre-planned under a 10b5‑1 plan and others were automatic sell‑to‑cover for taxes; these are routine and do not, by themselves, confirm a change in the insider's view of the company.
Insider Transaction Report
Form 4
Agarwal Arjun
Senior Vice President, Finance
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-06-12$12.50/sh+8,000$100,000→ 25,294 total - Exercise/Conversion
Common Stock
2026-06-12$34.39/sh+1,459$50,175→ 26,753 total - Sale
Common Stock
[F2][F3]2026-06-12$68.34/sh−1,859$127,048→ 24,894 total - Sale
Common Stock
[F2][F4]2026-06-12$69.85/sh−4,340$303,154→ 20,554 total - Sale
Common Stock
[F2][F5]2026-06-12$70.34/sh−3,260$229,306→ 17,294 total - Sale
Common Stock
[F6]2026-06-15$69.69/sh−395$27,528→ 16,899 total - Exercise/Conversion
Employee Stock Option (right to buy)
[F7]2026-06-12−8,000→ 110,000 totalExercise: $12.50Exp: 2035-01-21→ Common Stock (8,000 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
[F8]2026-06-12−1,459→ 62,708 totalExercise: $34.39Exp: 2036-01-22→ Common Stock (1,459 underlying)
Footnotes (8)
- [F1]Includes 888 shares acquired under the Oruka Therapeutics, Inc. stock purchase plan on June 8, 2026.
- [F2]These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.87 to $68.71, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (5) to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.07 to $70.06, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.07 to $70.86, inclusive.
- [F6]The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.
- [F7]The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
- [F8]The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Signature
/s/ Paul Quinlan, as attorney-in-fact for Arjun Agarwal|2026-06-15